COMBINATION THERAPY FOR THE TREATMENT OF OCULAR NEOVASCULAR DISORDERS
The invention features methods for treating a patient diagnosed with, or at risk of developing, a neovascular disorder by administering a PDGF antagonist and a VEGF antagonist to the patient. The invention also features a pharmaceutical composition containing a PDGF antagonist and a VEGF antagonist for the treatment or prevention of a neovascular disorder.
1 - 18 . (canceled)
19 . A composition comprising an effective amount of:
(a) a PDGF antagonist, wherein the PDGF antagonist is an antibody or binding fragment thereof; and
(b) a VEGF antagonist, wherein the VEGF antagonist is an antibody or binding fragment thereof.
20 . The composition of claim 19 , wherein the PDGF antagonist is a PDGF-B antagonist.
21 . The composition of claim 19 , wherein the PDGF antagonist is a PDGFR antagonist.
22 . The composition of claim 21 , wherein the PDGFR antagonist is a PDGFR-beta antagonist.
23 . The composition of claim 19 , wherein the VEGF antagonist is an anti-VEGF antibody or binding fragment thereof.
24 . The composition of claim 23 , wherein the anti-VEGF antibody or binding fragment thereof binds to VEGF-A.
25 . The composition of claim 24 wherein the anti-VEGF antibody or binding fragment thereof binds to human VEGF-A.
26 . The composition of claim 23 , wherein the anti-VEGF antibody or binding fragment thereof has:
(i) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 26 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 27, or
(ii) a light chain variable domain comprising the sequence of SEQ ID NO: 25 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 24.
27 . The composition of claim 19 , wherein the VEGF antagonist is 2C3.
28 . The composition of claim 21 , wherein the PDGFR antagonist is APB5.